Thoughts on Gilead’s Collaboration with Shoreline to Develop iPSC-derived Allogeneic Cell Therapies

On Thursday, June 17, Gilead (Kite) announced (press release) a strategic collaboration with Shoreline Biosciences to develop novel allogeneic cell therapies. Of note, the partnership will focus on the development of iPSC-derived CAR-NK therapies for hematological malignancies, with Gilead (Kite) having the possibility to include an iPSC-derived CAR-macrophage (CAR-M) program. Below, Celltelligence provides insights on Gilead’s (Kite) latest collaboration and the potential advantages CAR-NKs and CAR-Ms may have over CAR-T therapies.

About The Author

The Celltelligence Team

Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.


You’ll be able to access the full article from your Celltelligence Library after signing up.